Stockscreener 앱 받기
481.67
0.12%
0.60
전일 마감가:
$481.07
열려 있는:
$481.65
하루 거래량:
1.03M
Relative Volume:
0.88
시가총액:
$63.14B
수익:
$2.46B
순이익/손실:
$-319.09M
주가수익비율:
-195.25
EPS:
-2.4669
순현금흐름:
$-52.09M
1주 성능:
+4.61%
1개월 성능:
+6.63%
6개월 성능:
+105.35%
1년 성능:
+62.32%
1일 변동 폭
$476.44
$492.62
1주일 범위
$453.82
$492.62
52주 변동 폭
$205.87
$492.62
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
명칭
Alnylam Pharmaceuticals Inc
전화
(617) 551-8200
주소
675 WEST KENDALL STREET, CAMBRIDGE, MA
ALNY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
481.67 | 63.06B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
VRTX
Vertex Pharmaceuticals Inc
|
416.81 | 104.76B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
578.05 | 60.32B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
843.66 | 51.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
165.76 | 34.49B | 398.11M | -1.03B | -868.57M | -5.7032 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-04 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2025-08-04 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2025-07-30 | 재개 | Raymond James | Outperform |
| 2025-07-21 | 개시 | Truist | Buy |
| 2025-03-31 | 개시 | Redburn Atlantic | Buy |
| 2025-03-24 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-11-12 | 다운그레이드 | Wolfe Research | Peer Perform → Underperform |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-08-16 | 업그레이드 | Goldman | Neutral → Buy |
| 2024-02-16 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-02-15 | 개시 | Wolfe Research | Peer Perform |
| 2023-12-08 | 개시 | Wells Fargo | Equal Weight |
| 2023-10-11 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2023-09-29 | 개시 | Raymond James | Outperform |
| 2023-05-05 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | 개시 | SMBC Nikko | Neutral |
| 2023-03-21 | 개시 | Bernstein | Outperform |
| 2023-01-18 | 개시 | Canaccord Genuity | Buy |
| 2022-09-09 | 재개 | Morgan Stanley | Equal-Weight |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Neutral |
| 2022-06-27 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-06-07 | 개시 | William Blair | Outperform |
| 2022-04-25 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | 개시 | Citigroup | Buy |
| 2022-02-03 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-01-03 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | 업그레이드 | Goldman | Neutral → Buy |
| 2021-11-22 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-10-04 | 업그레이드 | UBS | Neutral → Buy |
| 2021-08-04 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-02-12 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-02-12 | 재확인 | H.C. Wainwright | Buy |
| 2021-01-25 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | 재개 | Berenberg | Hold |
| 2020-09-08 | 개시 | Citigroup | Buy |
| 2020-08-11 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-05-13 | 개시 | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-04-24 | 재개 | Evercore ISI | Outperform |
| 2020-03-19 | 개시 | Berenberg | Buy |
| 2019-12-19 | 재확인 | Chardan Capital Markets | Buy |
| 2019-11-20 | 개시 | Oppenheimer | Outperform |
| 2019-11-13 | 개시 | BofA/Merrill | Buy |
| 2019-05-23 | 재개 | Goldman | Neutral |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2019-03-06 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2019-03-05 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | 개시 | UBS | Neutral |
| 2018-10-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-08-13 | 재확인 | Stifel | Buy |
| 2018-08-07 | 업그레이드 | Stifel | Hold → Buy |
| 2018-05-04 | 재확인 | Stifel | Hold |
| 2018-03-28 | 개시 | Evercore ISI | In-line |
모두보기
Alnylam Pharmaceuticals Inc 주식(ALNY)의 최신 뉴스
What to do if you’re stuck in Alnylam Pharmaceuticals Inc.2025 EndofYear Setup & Verified Trade Idea Suggestions - newser.com
Why Alnylam Pharmaceuticals Inc. stock is recommended by analystsMarket Risk Analysis & Weekly High Return Opportunities - newser.com
Truist Securities Raises Price Target for Alnylam Pharmaceuticals (ALNY) by 16.56% | ALNY Stock News - GuruFocus
Alnylam stock price target raised to $535 from $459 by Truist Securities - Investing.com
Alnylam to Webcast Conference Call Discussing Third Quarter 2025 Financial Results - BioSpace
Alnylam Pharmaceuticals (ALNY): Assessing Valuation Following New Partnerships, Pipeline Progress, and Fresh Financing - Yahoo Finance
Responsive Playbooks and the ALNY Inflection - news.stocktradersdaily.com
Is the Options Market Predicting a Spike in Alnylam Pharmaceuticals Stock? - sharewise.com
Alnylam Pharmaceuticals stock hits all-time high at 484.5 USD By Investing.com - Investing.com Nigeria
Are You Looking for a Top Momentum Pick? Why Alnylam Pharmaceuticals (ALNY) is a Great Choice - Yahoo Finance
Custom watchlist performance reports with Alnylam Pharmaceuticals Inc.2025 Top Gainers & Fast Moving Stock Trade Plans - newser.com
Alnylam Pharmaceuticals stock hits all-time high at 484.5 USD - Investing.com India
What Catalysts Are Shaping the Evolving Narrative for Alnylam Pharmaceuticals? - Yahoo Finance
Is Alnylam Pharmaceuticals Inc. stock ready for breakoutAnalyst Upgrade & Free High Accuracy Swing Entry Alerts - newser.com
The Bull Case For Alnylam Pharmaceuticals (ALNY) Could Change Following Phase 3 ZENITH Study Launch for Zilebesiran - simplywall.st
Here's Why Alnylam Pharmaceuticals (ALNY) is a Strong Momentum Stock - Yahoo Finance
Is Alnylam Pharmaceuticals (ALNY) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Will Alnylam Pharmaceuticals Inc. stock sustain high P E ratiosJuly 2025 Update & Safe Capital Allocation Plans - newser.com
Has Alnylam Pharmaceuticals Inc. found a price floorMarket Risk Summary & Verified Swing Trading Watchlist - newser.com
JP Morgan Lowers Price Target for ALNY, Maintains Overweight Rat - GuruFocus
What earnings revisions data tells us about Alnylam Pharmaceuticals Inc.Weekly Stock Report & Fast Moving Trade Plans - newser.com
Alnylam Pharma Secures $500M Credit Agreement - MSN
Vontobel Holding Ltd. Has $951,000 Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Callan Family Office LLC Raises Stake in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals, Inc. (ALNY) Stock Analysis: A Biotech Leader with a Robust Pipeline and Strong Buy Ratings - DirectorsTalk Interviews
Sivik Global Healthcare LLC Takes Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Aberdeen Group plc Boosts Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals (ALNY): Valuation Snapshot Following New Phase 3 Data and Pipeline Progress - simplywall.st
Alnylam Pharmaceuticals (NASDAQ:ALNY) Receives Buy Rating from HC Wainwright - MarketBeat
H.C. Wainwright Reaffirms Their Buy Rating on Alnylam Pharma (ALNY) - The Globe and Mail
Is Alnylam Pharmaceuticals Inc. (DUL) stock attractive for dividend growthJuly 2025 Catalysts & High Accuracy Swing Trade Signals - newser.com
ALNY: HC Wainwright & Co. Reiterates Buy Rating with $570 Price Target | ALNY Stock News - GuruFocus
Is Alnylam Pharmaceuticals Inc. stock ready for a breakoutJuly 2025 Trade Ideas & Stock Timing and Entry Methods - newser.com
Using AI based signals to follow Alnylam Pharmaceuticals Inc.Trade Volume Summary & High Conviction Buy Zone Alerts - newser.com
What drives Alnylam Pharmaceuticals Inc stock priceGlobal Trade Effects & Access Risk Ratings for Every Stock - earlytimes.in
Alnylam and Regeneron Join Forces in Promising Alzheimer’s Study - TipRanks
KLP Kapitalforvaltning AS Has $16.01 Million Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Shell Asset Management Co. Purchases 1,602 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Mirae Asset Global Investments Co. Ltd. Has $1.56 Million Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Weiss Ratings Reaffirms "Sell (D-)" Rating for Alnylam Pharmaceuticals (NASDAQ:ALNY) - MarketBeat
Alnylam’s AMVUTTRA Reduces GI Events in ATTR-CM Patients, According to New HELIOS-B Data - MSN
Amyloidosis Clinical Market Outlook 2024-2034: Expanding Diagnostic Capabilities - openPR.com
RNAi: The Benefits Of Shooting The Messenger - Seeking Alpha
27 Analysts Assess Alnylam Pharmaceuticals: What You Need To Know - Benzinga
Did Amvuttra’s Phase 3 Update and ZENITH Trial Milestone Just Shift Alnylam’s (ALNY) Investment Narrative? - simplywall.st
Alnylam Pharmaceuticals (ALNY) Gets Target Price Boost from Morg - GuruFocus
Morgan Stanley Raises Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $475.00 - MarketBeat
Stifel Raises Price Target for ALNY; Maintains 'Buy' Rating | AL - GuruFocus
Smart tools for monitoring Alnylam Pharmaceuticals Inc.’s price action2025 Bull vs Bear & Short-Term Trading Alerts - newser.com
Alnylam Pharmaceuticals (NASDAQ:ALNY) Given New $495.00 Price Target at Stifel Nicolaus - MarketBeat
Morgan Stanley Raises Price Target on Alnylam Pharmaceuticals to $475 From $405, Keeps Equalweight Rating - MarketScreener
Alnylam Pharmaceuticals Inc (ALNY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.56%
0.50%
자본화:
|
볼륨(24시간):